Metraipolis › archive › dc_100644dba603
Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis — Europe PMC PMID:42137821
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42137821
- DOI
- 10.1093/noajnl/vdag013
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T13:08:05.084Z
- SHA-256 of the archived text
457e8e21170345bfd654a0e99f74b449f675e49af72206a469a23cfbdff43777- Stable URL of this page
https://metraipolis.com/documento/dc_100644dba603
How to cite
Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis — Europe PMC PMID:42137821 — Europe PMC (en), https://europepmc.org/article/MED/42137821 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_100644dba603 (Metraipolis archive dc_100644dba603, sha256 457e8e21170345bfd654a0e99f74b449f675e49af72206a469a23cfbdff43777)
BibTeX
@misc{dc100644dba603,
title = {Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis — Europe PMC PMID:42137821},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42137821},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_100644dba603; sha256 457e8e21170345bfd654a0e99f74b449f675e49af72206a469a23cfbdff43777},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42137821. Agents can read the archived copy with the MCP tool read_document.